Manni A, Arafah B, Pearson O H
Cancer. 1980 Dec 15;46(12 Suppl):2838-41. doi: 10.1002/1097-0142(19801215)46:12+<2838::aid-cncr2820461421>3.0.co;2-a.
This review presents our experience with the use of estrogen receptors (ER) and progesterone receptors (PgR) in the prediction of response to endocrine therapy in stage IV breast cancer. Presence of ER (> 3 fmol/mg cytosol protein) significantly predicted response to the antiestrogen tamoxifen and to hypophysectomy. ER-negative patients did not respond to either modality of therapy in our series. The absolute amount of ER did not significantly improve our ability to predict response to hormone treatment. In our experience, limited to a small number of patients, the presence of PgR in addition to ER did not increase the probability of response to endocrine therapy. Our findings underscore the usefulness of ER measurement in the prediction of response to either antiestrogen therapy or hypophysectomy in metastatic breast cancer.
本综述介绍了我们利用雌激素受体（ER）和孕激素受体（PgR）预测IV期乳腺癌内分泌治疗反应的经验。ER（>3 fmol/mg胞浆蛋白）的存在显著预测了对抗雌激素他莫昔芬和垂体切除术的反应。在我们的系列研究中，ER阴性的患者对这两种治疗方式均无反应。ER的绝对量并未显著提高我们预测激素治疗反应的能力。根据我们仅限于少数患者的经验，除ER外PgR的存在并未增加内分泌治疗反应的概率。我们的研究结果强调了ER测量在预测转移性乳腺癌抗雌激素治疗或垂体切除术反应中的有用性。
